Laxogenin
5alpha-hydroxy-laxogenin · 5α-OH-laxogenin · Smilagenone · brassinosteroid analog
Last updated
At a glance
Overview
What Laxogenin Actually Is#
Laxogenin is a steroidal sapogenin — a plant-derived spirostane that shares structural DNA with the brassinosteroid class. The commercial form sold across the supplement industry is almost always 5α-hydroxy-laxogenin, a semi-synthetic analog stabilized for oral dosing. It's the headline ingredient in a long list of "natural anabolic" products marketed to natty lifters, TRT-only users, and looksmaxxers who want a non-suppressive nudge to recovery and protein synthesis without touching the HPTA.
The appeal is mechanistic, not magical. The brassinosteroid class — best-studied via the analog 28-homobrassinolide — drives protein synthesis through PI3K/Akt signaling independent of the androgen receptor. That means no aromatization, no estrogen management, no PCT, no virilization concerns, and a dosing protocol that runs the same across the entire subject pool.
"Plant-derived brassinosteroid 28-homobrassinolide (HB) stimulated protein synthesis and inhibited protein degradation in L6 rat skeletal muscle cells via PI3K/Akt signaling independently of the androgen receptor." — Esposito et al., FASEB Journal (2011)
The honest framing: laxogenin is a modest recovery and recomp aid, not an AAS or SARM substitute. Realistic outcomes sit in the range of ~0.15 lb/week of lean mass on top of a structured training base, slightly improved between-session recovery, and better muscle retention through a cut. The community consensus from multi-week logs is roughly "5–10% on top of good training and nutrition" — useful as a bridge, a natty stack component, or a non-suppressive add-on to TRT, but disappointing for anyone expecting transformative results.
The sections below cover the documented dosing ladder (50–200 mg/day, split AM/PM with fat-containing meals), 8–12 week cycle structure, the strongest stacks (turkesterone, MK-677, epicatechin), realistic outcome expectations, side-effect profile, and the sourcing and purity issues that determine whether a given product actually contains what the label claims.
How Laxogenin works
PI3K/Akt Activation and Protein Synthesis#
The mechanistic foundation for laxogenin sits in the brassinosteroid class — plant-derived polyhydroxylated steroids that signal through PI3K/Akt in mammalian muscle tissue. The defining work here is Esposito et al. on 28-homobrassinolide (HB), the closest well-characterized analog. In L6 rat myotubes, HB simultaneously stimulated protein synthesis and inhibited protein degradation, with downstream phosphorylation of Akt and p70S6K driving mTORC1-mediated translation. Laxogenin shares the spirostane backbone and is presumed to act through the same pathway, though direct in vivo data on laxogenin itself remains thin.
"Plant-derived brassinosteroid 28-homobrassinolide (HB) stimulated protein synthesis and inhibited protein degradation in L6 rat skeletal muscle cells via PI3K/Akt signaling independently of the androgen receptor." — Esposito D. et al. FASEB Journal, 2011
The practical translation: a modest bump in net nitrogen balance — favoring lean-mass retention during a deficit and incremental gains during a surplus — without touching the androgen receptor.
Non-Androgenic, Non-Hormonal Signaling#
Brassinosteroids resemble animal steroid hormones structurally but do not bind the androgen receptor, estrogen receptor, or glucocorticoid receptor at physiologically relevant concentrations. The Hershberger assay on HB showed minimal androgenic activity even at high oral doses, and no measurable HPTA suppression in animal models.
"28-homobrassinolide increases in vivo food intake, body weight, and lean mass in healthy and castrated rats with minimal androgenic effects, supporting its anabolic potential via non-androgenic pathways." — Esposito D. et al. FASEB Journal, 2011
This is the entire commercial pitch: anabolic signaling without aromatization, without 5α-reduction, without LH/FSH shutdown, and without the lipid and hair-loss collateral that come with AAS. It is also why no PCT is required and why dosing is identical across the full subject pool. The trade-off is honest — the effect size is a fraction of what hormonal compounds deliver.
Anti-Catabolic and Cortisol-Attenuation Effects#
Beyond the synthesis side of the equation, the Esposito data showed inhibition of protein degradation pathways — implicating attenuation of the ubiquitin-proteasome system and, by extension, blunting of cortisol-mediated proteolysis. In community practice this is the most consistently reported subjective benefit: reduced soreness between sessions, better recovery on volume blocks, and lean-mass preservation through aggressive cuts. It is also the rationale for stacking laxogenin into high-stress training phases (Smolov, GVT, peaking blocks) and into caloric deficits where cortisol is structurally elevated.
Structural Basis — The Spirostane Backbone#
Laxogenin belongs to the spirostane-type sapogenins, sharing the polyhydroxylated 5α-cholestane scaffold that defines anabolic activity in this chemical class. The 5α-hydroxy variant sold commercially is a semi-synthetic modification intended to improve oral stability and absorption of an otherwise poorly bioavailable lipophilic molecule.
"The class of spirostane-type brassinosteroids, including laxogenin, share a polyhydroxylated steroidal backbone, providing a basis for their anabolic signaling activity in plant and mammalian systems." — Tian J. et al. Tetrahedron Letters, 2024
The lipophilicity is why co-administration with dietary fat is the standard protocol — absorption is meaningfully improved when dosed with a meal containing 15g+ of fat versus dosed fasted.
Why Onset Is Slow#
Unlike acute ergogenics (caffeine, citrulline, creatine saturation), brassinosteroid signaling works through chronic upregulation of translational machinery. Measurable effects on recovery and pump typically emerge at weeks 4–6, with peak subjective response in the 6–10 week window. This is consistent with the Esposito rat data, where lean-mass and fiber-composition shifts required sustained dosing rather than acute exposure. The practical implication: short 4-week bottles are wasted product, and the literature supports cycles of 8–12 weeks minimum to evaluate response honestly.
"Over the 9-week run, strength and recovery showed consistent progression, with muscle retention maintained during a slight caloric deficit while using turkesterone and laxogenin daily." — u/arobbedrabbit, r/Supplements, 2021
Tied back to outcomes the reader cares about: laxogenin is a recovery and lean-mass-retention compound with a modest hypertrophy signal, not a strength-or-size transformative agent. The 5/10 recovery score and 3/10 muscle-growth score in the scalar profile reflect exactly that — meaningful for the natty, TRT-only, or between-cycle user; underwhelming for anyone benchmarking against real AAS or SARM cycles.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 50–75 mg | Twice daily | Documented entry-level range |
| Mid | 75–100 mg | Twice daily | Most commonly studied range |
| High | 100–200 mg | Twice daily | Split AM/PM with meals. Lipophilic sapogenin — co-administration with dietary fat is the standard approach. Onset is slow; effects typically emerge at weeks 4–6. |
Cycle length & outcomes
Documented cycle
8–12 weeks
Plateau after
12 wks
Cycle Structure#
Laxogenin is a slow, non-suppressive supplement — there is no HPTA shutdown, no aromatization, and no need for PCT or ancillaries. The practical implication: cycles run long, and short bottles are wasted money. The Esposito rat work on the parent brassinosteroid established the anabolic signaling through PI3K/Akt without androgen receptor binding, which is why protocols can extend well past the 4–8 week window typical of hormonal compounds.
"28-homobrassinolide increases in vivo food intake, body weight, and lean mass in healthy and castrated rats with minimal androgenic effects, supporting its anabolic potential via non-androgenic pathways." — Esposito et al., FASEB Journal (2011)
Dose Ladder by Goal#
| Goal | Cycle Length | Daily Dose | Split |
|---|---|---|---|
| First exposure / tolerance check | 8 weeks | 50–75mg | Single dose AM with food |
| Natty recomp | 10–12 weeks | 100mg | 50mg AM / 50mg PM with meals |
| Bridge between AAS or SARM cycles | 8–12 weeks | 100–150mg | Split AM/PM |
| Cut-phase muscle preservation | 10–12 weeks | 100–150mg | Split AM/PM |
| TRT add-on / volume block support | 12 weeks | 150–200mg | 2–3× daily with meals |
Onset Timing#
The single most common community complaint about laxogenin is that 4-week runs do nothing — and that complaint is structurally correct. The compound is slow.
- Weeks 1–3: No subjective change. The protocol simply runs in the background.
- Weeks 4–6: Recovery and pump improvements emerge first. Reduced between-session soreness is the most consistent early signal.
- Weeks 6–10: Peak subjective response — strength progression smooths out, lean mass accrues at ~0.1–0.15 lb/week above training baseline.
- Weeks 10–12: Plateau. The dose-response curve flattens; pushing past 12 weeks shows diminishing returns rather than continued accrual.
This is why 8 weeks is the floor and 12 weeks is the standard ceiling. Anyone evaluating laxogenin at week 3 and concluding it doesn't work has not actually evaluated laxogenin.
Loading and Tapering#
No loading phase. Steady-state dosing from day one is the standard approach — the slow onset isn't a kinetics problem (the half-life is short enough that twice-daily dosing maintains stable exposure) but a downstream adaptation problem at the muscle level.
No taper required. The compound is non-suppressive, non-hormonal, and discontinuation produces no rebound. Cycles end cleanly.
Off-time between cycles: 4 weeks is a reasonable rest window, primarily to assess whether continued use is producing returns rather than out of any physiological necessity. Many users run laxogenin nearly year-round as a TRT add-on or low-stakes background compound.
Administration Notes#
5α-hydroxy-laxogenin is a lipophilic sapogenin with poor inherent oral bioavailability. The protocol calls for:
- Co-administration with dietary fat. A meal containing 15g+ of fat substantially improves absorption versus fasted dosing.
- Twice-daily splits for doses ≥100mg/day. The functional half-life inferred from community practice is in the 6–8 hour range; single daily dosing of 150–200mg leaves long troughs.
- Capsule vs. bulk powder: Both work. Bulk powder is dramatically cheaper at 100–200mg/day but demands a milligram scale and trust in vendor COAs.
Bloodwork Cadence#
Not strictly required at modest doses, but reasonable due diligence for anyone running 150mg+ for a full 12-week cycle:
| Timepoint | Panel |
|---|---|
| Baseline (pre-cycle) | CMP, lipid panel |
| Week 8–12 | CMP, lipid panel |
The homobrassinolide rat data showed no hepatotoxicity, and human reports of liver or lipid disturbance are essentially absent — but human safety data on laxogenin specifically is thin enough that baseline + endpoint markers are cheap insurance, particularly when stacked with other oral compounds.
Realistic Expectations#
Laxogenin is a 5–10% on top of good training and nutrition compound. The published anabolic data is for homobrassinolide, not laxogenin, and the translation to human muscle growth is modest. The 9-week turkesterone + laxogenin log on r/Supplements captured the realistic ceiling:
"Over the 9-week run, strength and recovery showed consistent progression, with muscle retention maintained during a slight caloric deficit while using turkesterone and laxogenin daily." — u/arobbedrabbit, r/Supplements (2021)
That's the lane: smoother recovery, modest strength progression, lean-mass preservation on a deficit, and a clean side-effect profile. Anyone framing it as a SARM or oral AAS alternative is selling something. Anyone framing it as a long, non-suppressive recovery and recomp adjunct is using it correctly.
Body Transformation Preview
Lean Mass Gain
1.6 lbs
1.2–2.0 lbs range
Fat Loss
0.0 lbs
0.0–0.0 lbs range
Lean Gain by Week
Risks & mistakes
Common (most users)#
- Mild GI upset / nausea — most often at the 150–200mg/day end of the range, or when a full dose is administered on an empty stomach. Laxogenin is a lipophilic sapogenin; splitting the daily dose AM/PM and pairing each portion with a fat-containing meal resolves this in nearly all cases.
- Transient headaches — reported in a minority of subjects during the first 1–2 weeks. Usually self-limiting. Hydration and ensuring the dose is taken with food rather than fasted typically clears it.
- No noticeable effect for the first 3–4 weeks — not an adverse effect per se, but the single most common complaint. Onset is genuinely slow; the protocol calls for an 8–12 week minimum run before judging response.
- Mild appetite increase — consistent with the homobrassinolide rodent data showing increased food intake (Esposito et al. 2011). Generally welcome in a lean-gain or recomp context; trivially managed on a cut by sticking to the meal plan.
Uncommon (dose-dependent or individual)#
- Persistent GI discomfort at 150–200mg/day — when splitting with food does not resolve it, the protocol calls for dropping back to 100mg/day. The dose-response curve plateaus quickly, so the higher end is rarely worth pushing through GI distress.
- Mild lipid shifts — not documented in the rodent data, but worth a baseline + 8–12 week lipid panel for anyone running 150mg+ daily, particularly when stacked with orals, MK-677, or anything else that nudges HDL/LDL.
- Sleep disturbance from late-evening dosing — uncommon, but the PM dose is best administered with dinner rather than immediately pre-bed for sensitive subjects.
- No subjective effect at all — a real subset of users report nothing meaningful even after a full 12-week run at 150mg/day. Laxogenin is a modest compound; non-response is a legitimate outcome and not a reason to escalate dose indefinitely.
Rare but serious#
- No serious adverse events have been documented in the available rodent literature for homobrassinolide at oral doses up to 60 mg/kg (Esposito et al. 2011), and no formal human safety signals have surfaced from the supplement-market exposure of the past decade.
- Product-purity-related events are the realistic concern. The "laxogenin" supplement category has a history of under-dosed, contaminated, or spiked products. Any unexpected androgenic signal (acne flare, libido shift, mood change, HPTA-style symptoms) on a labeled-laxogenin product points to an adulterated SKU rather than the molecule itself — discontinue immediately and source from a vendor with third-party COAs.
- Hepatic markers — no hepatotoxicity has been reported, but human liver-marker data is essentially absent. Subjects stacking laxogenin with 17-aa orals should attribute any AST/ALT elevation to the oral and not assume laxogenin is neutral by default.
Hard contraindications#
- Active malignancy — laxogenin and the brassinosteroid class signal through PI3K/Akt (Esposito et al. 2011), a pathway frequently dysregulated in tumor biology. Not a line to cross.
- Pregnancy and lactation — no reproductive or developmental safety data exists. Excluded.
- Adulterated / unverified products — not a contraindication to the molecule, but a hard line on sourcing. Caps from no-name brands without a COA are not equivalent to bulk powder from a tested vendor.
Gender and PCT considerations#
Laxogenin is non-androgenic, non-aromatizing, and does not bind the androgen receptor in vitro (Esposito et al. 2011). The Hershberger assay in castrated rats showed minimal androgenic activity even at 60 mg/kg oral. The practical consequences:
- Female subjects dose identically to male subjects. No documented virilization risk — no voice changes, hair pattern shifts, or clitoral effects in the available literature. This is one of the few "anabolic-adjacent" compounds where standard dosing applies across the full subject pool.
- PCT is not required. LH, FSH, and endogenous testosterone are unaffected in animal models. This is the entire reason laxogenin occupies the bridge / between-cycle and TRT add-on niches — it can be run continuously through the off-cycle window without complicating HPTA recovery, and layered onto a stable TRT base without escalating suppression.
- Fertility / semen quality — no signal in either direction. Not a concern for users planning near-term conception.
Honest framing: the side-effect profile is the single strongest argument for laxogenin existing. It is a modest compound with a clean ledger — manageable GI at the top of the dose range, a slow onset that punishes impatience, and a sourcing problem that lives in the supplement industry rather than in the molecule itself.
FAQ — Laxogenin
Research & citations
5 studies cited on this page.
Conclusion
Laxogenin slots in as a non-suppressive, well-tolerated recovery aid and bridge agent — best thought of as a modest but reliable adjunct for physique-focused users seeking gradual improvements.
Key takeaways:
- Standard dose: 100–200 mg/day oral, split AM/PM with meals, for 8–12 weeks
- Lipophilic sapogenin — co-administration with dietary fat supports absorption
- Onset is slow; meaningful effects on recovery and muscle retention typically appear after 4–6 weeks
- Stacking options: frequently run with turkesterone, creatine, or MK-677 for additive recovery and recomp benefits
- Safety profile is favorable: non-androgenic, non-suppressive, no PCT required (Esposito et al., 2011), but product purity and sourcing remain critical
- Expect a modest bump in strength and recovery (muscle growth score: 3/6) — results are incremental, not transformational
For anyone building a natty, TRT, or bridge stack, laxogenin offers accessible, low-risk support, provided expectations are realistic and the product is sourced from a reputable supplier.